KRYSKrystal Biotech, Inc.
Is the price fair?
A demanding price: priced for a lot of growth and rich vs its sector.
Priced for ~15% a year FCF growth. The price already bakes in strong, sustained growth.
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What KRYS's price assumes
Krystal Biotech, Inc. trades at 41.6× earnings against 18.8× for the median Biotechnology name, more expensive than its own group.
Trailing P/E · Biotechnology median 18.8 · 2.21× the median: the market pays up for this one
- Price / sales
- 27.3
Price / sales · today's price, fiscal year to Dec 31, 2025
- Free cash flow yield
- 2.4%
Free cash flow yield · Biotechnology median 3.6%
- Growth the price implies
- +15%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 8.70
- EV / EBITtoday's price, fiscal year to Dec 31, 2025
- 60.6
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 25.1
- Healthcare median P/E509 names
- 26.2
- Biotechnology median P/E244 names
- 18.8
- Free cash flow, trailing twelve months
- $258M
- Market capitalisation
- $10.6B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.